相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)
Keun-Wook Lee et al.
GASTRIC CANCER (2021)
Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials
D. E. Magee et al.
ANNALS OF ONCOLOGY (2020)
Combination versus single-agent as palliative chemotherapy for gastric cancer
Jin-Hyuk Choi et al.
BMC CANCER (2020)
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial
Alison Birtle et al.
LANCET (2020)
A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
Shoji Nagao et al.
JOURNAL OF OVARIAN RESEARCH (2020)
Amphiphilic star copolymers-mediated co-delivery of doxorubicin and avasimibe for effective combination chemotherapy
Ting Bai et al.
JOURNAL OF MATERIALS SCIENCE (2020)
COMBINATION CHEMOTHERAPY WITH A SHOCKING RESULT
Leonard Genovese et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Synergistic Chemotherapy for Breast Cancer and Breast Cancer Brain Metastases via Paclitaxel-Loaded Oleanolic Acid Nanoparticles
Youmei Bao et al.
MOLECULAR PHARMACEUTICS (2020)
Risk Associated with Severe Hematological Toxicity in Patients with Urothelial Cancer Receiving Combination Chemotherapy of Gemcitabine and Cisplatin
Noriko Takahashi et al.
CHEMOTHERAPY (2020)
Gut microbiome, big data and machine learning to promote precision medicine for cancer
Giovanni Cammarota et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Curcumin in cancer therapy: A novel adjunct for combination chemotherapy with paclitaxel and alleviation of its adverse effects
Milad Ashrafizadeh et al.
LIFE SCIENCES (2020)
Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance
Dimas Carolina Belisario et al.
CELLS (2020)
Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β-catenin pathway in NSCLC
Jianmin Wang et al.
CELL PROLIFERATION (2019)
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian Tian et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Jean-Louis Pujol et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study
Hitomi Hara et al.
BMC CANCER (2019)
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
Ronan Flippot et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
Maud Toulmonde et al.
LANCET ONCOLOGY (2019)
A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1
Anastasia De Luca et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
Fei Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cancer and Mediterranean Diet: A Review
Maria Chiara Mentella et al.
NUTRIENTS (2019)
Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer
Wan-Cai Que et al.
ANTI-CANCER DRUGS (2019)
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial
Harriet M. Kluger et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Exosomes from hyperglycemia-stimulated vascular endothelial cells contain versican that regulate calcification/senescence in vascular smooth muscle cells
Shuang Li et al.
CELL AND BIOSCIENCE (2019)
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
Ulrich Keilholz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Drug development in the era of precision medicine
Sarah A. Dugger et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Natural scaffolds in anticancer therapy and precision medicine
Aloran Mazumder et al.
BIOTECHNOLOGY ADVANCES (2018)
Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study
Hiroyuki Ohnuma et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer
Yan-qin Lan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study
Arndt Vogel et al.
EUROPEAN JOURNAL OF CANCER (2018)
Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
Conor E. Steuer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles et al.
LANCET (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer
Matthew T. McKenna et al.
TRANSLATIONAL ONCOLOGY (2018)
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer
Francesca Toffalorio et al.
Oncotarget (2018)
Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1
Juan Chen et al.
CANCER MEDICINE (2018)
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y. -J. Bang et al.
ANNALS OF ONCOLOGY (2018)
Precision medicine in head and neck cancer
Orit Kaidar-Person et al.
DRUG RESISTANCE UPDATES (2018)
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
Fabrice Barlesi et al.
LANCET ONCOLOGY (2018)
Synergistic combination chemotherapy using carrier-free celastrol and doxorubicin nanocrystals for overcoming drug resistance
Yating Xiao et al.
NANOSCALE (2018)
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The growing role of precision and personalized medicine for cancer treatment
Paulina Krzyszczyk et al.
TECHNOLOGY (2018)
miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells
Weihua Zhang et al.
JOURNAL OF DRUG TARGETING (2017)
Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin
Mengjie Rui et al.
MOLECULAR PHARMACEUTICS (2017)
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance
Fang Li et al.
EUROPEAN JOURNAL OF CANCER (2017)
Recent omics technologies and their emerging applications for personalised medicine
Dong-Hyuk Kim et al.
IET SYSTEMS BIOLOGY (2017)
Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov
Aidan Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review
Gwenalyn Garcia et al.
JOURNAL OF GASTROINTESTINAL CANCER (2017)
A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer
Chih-Yang Huang et al.
BIOMEDICINE-TAIWAN (2017)
Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma
Dunwan Zhu et al.
ACTA BIOMATERIALIA (2017)
Synergistic Cisplatin/Doxorubicin Combination Chemotherapy for Multidrug-Resistant Cancer via Polymeric Nanogels Targeting Delivery
Haiqiu Wu et al.
ACS APPLIED MATERIALS & INTERFACES (2017)
Modifiable and non-modifiable risk factors for pancreatic cancer: A review
Shallu Midha et al.
CANCER LETTERS (2016)
The p90rsk-mediated signaling of ethanol-induced cell proliferation in HepG2 cell line
Han Sang Kim et al.
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
Mitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer Chemotherapy
Kimitoshi Kohno et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells
Mariana Segovia-Mendoza et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
Nirmala Chandralega Kampan et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Protein Kinase Cα Mediates Erlotinib Resistance in Lung Cancer Cells
Mahlet B. Abera et al.
MOLECULAR PHARMACOLOGY (2015)
Etoposide resistance in MCF-7 breast cancer cell line is marked by multiple mechanisms
Aktan Alpsoy et al.
BIOMEDICINE & PHARMACOTHERAPY (2014)
lDNA DSB repair pathway choice: an orchestrated handover mechanism
A. Kakarougkas et al.
BRITISH JOURNAL OF RADIOLOGY (2014)
MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET
Jian-Ya Zhou et al.
CANCER LETTERS (2014)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Nemo-like kinase is critical for p53 stabilization and function in response to DNA damage
H-H Zhang et al.
CELL DEATH AND DIFFERENTIATION (2014)
Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
Lucas de Sousa Cavalcante et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle
Jaromir Gumulec et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Proteolytic Degradation of Topoisomerase II (Top2) Enables the Processing of Top2.DNA and Top2.RNA Covalent Complexes by Tyrosyl-DNA-Phosphodiesterase 2 (TDP2)
Rui Gao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
An overview of doxorubicin formulations in cancer therapy
Sangeeta Rivankar
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2014)
Harnessing the immune system for the treatment of breast cancer
Xinguo Jiang
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B (2014)
Spectroscopic detection of etoposide binding to chromatin components: The role of histone proteins
Elham Chamani et al.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY (2014)
TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro
An-Cong Wang et al.
ONCOLOGY LETTERS (2014)
Targeting PI3K/Akt/mTOR signaling in cancer
Camillo Porta et al.
FRONTIERS IN ONCOLOGY (2014)
Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin β1/Src/Akt-Driven Bypass Signaling
Rina Kanda et al.
CANCER RESEARCH (2013)
MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells
Hiroaki Nagano et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
An Undesired Effect of Chemotherapy GEMCITABINE PROMOTES PANCREATIC CANCER CELL INVASIVENESS THROUGH REACTIVE OXYGEN SPECIES-DEPENDENT, NUCLEAR FACTOR κB- AND HYPOXIA-INDUCIBLE FACTOR 1α-MEDIATED UP-REGULATION OF CXCR4
Sumit Arora et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Oktay Tacar et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2013)
Combined Treatment with Erlotinib and a Transforming Growth Factor-β Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non-Small-Cell Lung Cancer Cells
Masakuni Serizawa et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Thomas Bachelot et al.
LANCET ONCOLOGY (2013)
The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family
N. Skrypek et al.
ONCOGENE (2013)
RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth
Y. Romeo et al.
ONCOGENE (2013)
Induction of Autophagy Is an Early Response to Gefitinib and a Potential Therapeutic Target in Breast Cancer
Wieslawa H. Dragowska et al.
PLOS ONE (2013)
Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity
Frederik Koepper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Pre-mRNA processing factors meet the DNA damage response
Alessandra Montecucco et al.
Frontiers in Genetics (2013)
Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma
Jun Huang et al.
AUTOPHAGY (2012)
Regulation and function of the RSK family of protein kinases
Yves Romeo et al.
BIOCHEMICAL JOURNAL (2012)
Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review
Cheng-Bo Han et al.
CANCER INVESTIGATION (2012)
Inhibition of ATM blocks the etoposide-induced DNA damage response and apoptosis of resting human T cells
Z. Korwek et al.
DNA REPAIR (2012)
CXCL12/CXCR4 Protein Signaling Axis Induces Sonic Hedgehog Expression in Pancreatic Cancer Cells via Extracellular Regulated Kinase- and Akt Kinase-mediated Activation of Nuclear Factor κB IMPLICATIONS FOR BIDIRECTIONAL TUMOR-STROMAL INTERACTIONS
Ajay P. Singh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice
Alexandra Sevko et al.
JOURNAL OF IMMUNOTOXICOLOGY (2012)
Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner
Tillmann Michels et al.
JOURNAL OF IMMUNOTOXICOLOGY (2012)
Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells
Shingo Kagawa et al.
JOURNAL OF SURGICAL RESEARCH (2012)
Expression of TopBP1 in hereditary breast cancer
Ewa Forma et al.
MOLECULAR BIOLOGY REPORTS (2012)
Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells
Shu-Yan Han et al.
LUNG CANCER (2012)
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Andrew C. Hsieh et al.
NATURE (2012)
Phosphorylation of SRSF1 is modulated by replicational stress
Valentina Leva et al.
NUCLEIC ACIDS RESEARCH (2012)
Multiple Analyses of G-Protein Coupled Receptor (GPCR) Expression in the Development of Gefitinib-Resistance in Transforming Non-Small-Cell Lung Cancer
Naoko Kuzumaki et al.
PLOS ONE (2012)
Target genes of Topoisomerase IIβ regulate neuronal survival and are defined by their chromatin state
Vijay K. Tiwari et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Gregg L. Semenza
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies
Lise Willems et al.
CURRENT ONCOLOGY REPORTS (2012)
Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family
Ying-Nai Wang et al.
CELL AND BIOSCIENCE (2012)
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Yongsheng Wang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
DNA Repair and Cancer Therapy: Targeting APE1/Ref-1 Using Dietary Agents
Julian J. Raffoul et al.
JOURNAL OF ONCOLOGY (2012)
Mechanism of Cell Adaptation When and How Do Cancer Cells Develop Chemoresistance?
Valentina Fodale et al.
CANCER JOURNAL (2011)
Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells
Masanori Nakashima et al.
CANCER LETTERS (2011)
Hedgehog signaling pathway as a therapeutic target in various types of cancer
Hideya Onishi et al.
CANCER SCIENCE (2011)
Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways
Nadine Rohwer et al.
DRUG RESISTANCE UPDATES (2011)
Stromal biology and therapy in pancreatic cancer
Albrecht Neesse et al.
GUT (2011)
Selective Impairment of CD4+CD25+Foxp3+Regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis
Nan Liu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
Activation of AMP-Activated Protein Kinase is Involved in Vincristine-Induced Cell Apoptosis in B16 Melanoma Cell
Min-Bin Chen et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib
Kenichi Suda et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1
Min-Kyoung Kim et al.
MOLECULAR CANCER (2011)
A Screening of a Library of T7 Phage-Displayed Peptide Identifies E2F-4 as an Etoposide-Binding Protein
Mihoko Takami et al.
MOLECULES (2011)
CD4+Foxp3+ Regulatory T-cell Impairment by Paclitaxel is Independent of Toll-like Receptor 4
Y. Zhu et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2011)
Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
Yonghao Yu et al.
SCIENCE (2011)
The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
Peggy P. Hsu et al.
SCIENCE (2011)
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
Chyuan-Chuan Wu et al.
SCIENCE (2011)
Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
Cheryl A. Sherman-Baust et al.
JOURNAL OF OVARIAN RESEARCH (2011)
Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
Ana-Maria Florea et al.
Cancers (2011)
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy
S. Singh et al.
BRITISH JOURNAL OF CANCER (2010)
Alternative Splicing of Caspase 9 Is Modulated by the Phosphoinositide 3-Kinase/Akt Pathway via Phosphorylation of SRp30a
Jacqueline C. Shultz et al.
CANCER RESEARCH (2010)
An Alternative Splicing Network Links Cell-Cycle Control to Apoptosis
Michael J. Moore et al.
CELL (2010)
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
Lukas W. Pfannenstiel et al.
CELLULAR IMMUNOLOGY (2010)
CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Beverly A. Teicher et al.
CLINICAL CANCER RESEARCH (2010)
Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review
Suman Lal et al.
CURRENT DRUG METABOLISM (2010)
Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress
Tanja Hadzic et al.
FREE RADICAL BIOLOGY AND MEDICINE (2010)
ERCC1: impact in multimodality treatment of upper gastrointestinal cancer
Ralf Metzger et al.
FUTURE ONCOLOGY (2010)
miR-29 Modulates Wnt Signaling in Human Osteoblasts through a Positive Feedback Loop
Kristina Kapinas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
TGF-β Signaling Pathway in Lung Adenocarcinoma Invasion
Rebecca L. Toonkel et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse
Alain P. Vicari et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Paclitaxel Directly Binds to Bcl-2 and Functionally Mimics Activity of Nur77
Cristiano Ferlini et al.
CANCER RESEARCH (2009)
The role of topoisomerase IIα and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients
Catherine Oakman et al.
CANCER TREATMENT REVIEWS (2009)
Modes of p53 Regulation
Jan-Philipp Kruse et al.
CELL (2009)
Akt-dependent and -independent mechanisms of mTOR regulation in cancer
Regan M. Memmott et al.
CELLULAR SIGNALLING (2009)
Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe
Bharat B. Aggarwal et al.
CLINICAL CANCER RESEARCH (2009)
Paclitaxel and immune system
Aqeel Javeed et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell et al.
GASTROENTEROLOGY (2009)
Hypoxia-inducible Factor-Dependent Repression of Equilibrative Nucleoside Transporter 2 Attenuates Mucosal Inflammation During Intestinal Hypoxia
Julio C. Morote-Garcia et al.
GASTROENTEROLOGY (2009)
Effect of sirolimus on urinary bladder cancer T24 cell line
Rosario Pinto-Leite et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations
Ramon Kaneno et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
ABCB8 Mediates Doxorubicin Resistance in Melanoma Cells by Protecting the Mitochondrial Genome
Aaron M. Elliott et al.
MOLECULAR CANCER RESEARCH (2009)
A human 5′-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage
Felipe Cortes Ledesma et al.
NATURE (2009)
Epidemiology of pancreatic cancer: an overview
Sara Raimondi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2009)
Molecular mechanisms of mTOR-mediated translational control
Xiaoju Max Ma et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/β-catenin pathway
M. Flahaut et al.
ONCOGENE (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
DNA topoisomerase II and its growing repertoire of biological functions
John L. Nitiss
NATURE REVIEWS CANCER (2009)
Annexin II Overexpression Predicts Rapid Recurrence after Surgery in Pancreatic Cancer Patients Undergoing Gemcitabine-Adjuvant Chemotherapy
Shigetsugu Takano et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
P. M. O'Brien et al.
BRITISH JOURNAL OF CANCER (2008)
Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells
Kehy L. Mueller et al.
CANCER RESEARCH (2008)
Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells
Wen Yang et al.
CANCER RESEARCH (2008)
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
Jennifer M. Bailey et al.
CLINICAL CANCER RESEARCH (2008)
Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy
Lei Zhang et al.
CLINICAL IMMUNOLOGY (2008)
A role for ceramide in driving cancer cell resistance to doxorubicin
Yong-Yu Liu et al.
FASEB JOURNAL (2008)
HER-2 and topoisomerase II as predictors of response to chemotherapy
Kathleen I. Pritchard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
Jorge A. Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2008)
AMPK phosphorylation of raptor mediates a metabolic checkpoint
Dana M. Gwinn et al.
MOLECULAR CELL (2008)
Cancer is a Preventable Disease that Requires Major Lifestyle Changes
Preetha Anand et al.
PHARMACEUTICAL RESEARCH (2008)
Topoisomerase levels determine chemotherapy response in vitro and in vivo
Darren J. Burgess et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment
Clorinda Schettino et al.
Expert Review of Respiratory Medicine (2008)
Wnt signalling and its impact on development and cancer
Alexandra Klaus et al.
NATURE REVIEWS CANCER (2008)
Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling
Nicola Normanno et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells
Janna Krol et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Common Activation of Canonical Wnt Signaling in Pancreatic Adenocarcinoma
Marina Pasca di Magliano et al.
PLOS ONE (2007)
p18Hamlet mediates different p53-dependent responses to DNA damage-inducing agents
Vanesa Lafarga et al.
CELL CYCLE (2007)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase
Emma V. Jones et al.
BIOCHEMICAL JOURNAL (2007)
Topoisomerase II-drug interaction domains: Identification of substituents on etoposide that interact with the enzyme
Amy M. Wilstermann et al.
BIOCHEMISTRY (2007)
Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs
Mamatha S. Nayak et al.
CANCER RESEARCH (2007)
被撤回的出版物: Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation (Retracted article. See vol. 78, pg. 4097, 2018)
Chang-Shi Chen et al.
CANCER RESEARCH (2007)
Novel action of paclitaxel against cancer cells: Bystander effect mediated by reactive oxygen species
Jerome Alexandre et al.
CANCER RESEARCH (2007)
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer
Shin Nakahira et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
The gene encoding the splicing factor SF2/ASF is a proto-oncogene
Rotem Karni et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Aberrant expression of TopBP1 in breast cancer
J. J. Going et al.
HISTOPATHOLOGY (2007)
DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells
M. Katayama et al.
CELL DEATH AND DIFFERENTIATION (2007)
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
Y. Nakano et al.
BRITISH JOURNAL OF CANCER (2007)
Molecular mechanisms of resistance and toxicity associated with platinating agents
Cara A. Rabik et al.
CANCER TREATMENT REVIEWS (2007)
Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells
Laszlo Markasz et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Apoptosis: A review of programmed cell death
Susan Elmore
TOXICOLOGIC PATHOLOGY (2007)
A protease pathway for the repair of topoisomerase II-DNA covalent complexes
Ailing Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The internalization and degradation of human copper transporter 1 following cisplatin exposure
Alison K. Holzer et al.
CANCER RESEARCH (2006)
Cisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor
S. E. Winograd-Katz et al.
ONCOGENE (2006)
Role of topoisomerase IIβ in the expression of developmentally regulated genes
Yi Lisa Lyu et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin
Alison K. Holzer et al.
MOLECULAR PHARMACOLOGY (2006)
Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis
Peng Wang et al.
CELLULAR SIGNALLING (2006)
Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer
Zhenfeng Duan et al.
CLINICAL CANCER RESEARCH (2006)
Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways
T-H Wang et al.
ONCOGENE (2006)
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents
Martin Monte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage
Mobeen Malik et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
N Normanno et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
Aberrant Wnt/β-catenin signaling in pancreatic adenocarcinoma
Gang Zeng et al.
NEOPLASIA (2006)
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine
E Giovannetti et al.
CANCER RESEARCH (2006)
The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions
S Yoon et al.
GROWTH FACTORS (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
The dispersal of replication proteins after etoposide treatment requires the cooperation of Nbs1 with the ataxia telangiectasia Rad3-related/Chk1 pathway
R Rossi et al.
CANCER RESEARCH (2006)
Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations
S Nakada et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas
E Yakirevich et al.
GYNECOLOGIC ONCOLOGY (2006)
HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia
HK Eltzschig et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival
LM Karnitz et al.
MOLECULAR PHARMACOLOGY (2005)
AKT crystal structure and AKT-specific inhibitors
CC Kumar et al.
ONCOGENE (2005)
mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events
MK Holz et al.
CELL (2005)
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition
S Thomson et al.
CANCER RESEARCH (2005)
In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant
AM Bergman et al.
CANCER RESEARCH (2005)
Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cδ
A Basu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways
S Hart et al.
BIOLOGICAL CHEMISTRY (2005)
The coordinate regulation of the p53 and rnTOR pathways in cells
ZH Feng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer
G Giaccone
JOURNAL OF CLINICAL ONCOLOGY (2005)
Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production
M Kubo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches
M Galanski et al.
CURRENT MEDICINAL CHEMISTRY (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
Epidermal growth factor receptor mutations in patients with non-small cell lung cancer
BE Johnson et al.
CANCER RESEARCH (2005)
Caspase activation - stepping on the gas or releasing the brakes? Lessons from humans and flies
GS Salvesen et al.
ONCOGENE (2004)
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine
K Yokoi et al.
CLINICAL CANCER RESEARCH (2004)
PI3K/Akt signalling pathway and cancer
JAF Vara et al.
CANCER TREATMENT REVIEWS (2004)
A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin
GJ Browne et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells
A Habiro et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells
AK Holzer et al.
CLINICAL CANCER RESEARCH (2004)
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
SH Um et al.
NATURE (2004)
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer
BA Schiff et al.
CLINICAL CANCER RESEARCH (2004)
Counting on mitogen-activated protein kinases - ERKs 3, 4, 5, 6, 7 and 8
MA Bogoyevitch et al.
CELLULAR SIGNALLING (2004)
Role of non-selective adenosine receptor blockade and phosphodiesterase inhibition in cisplatin-induced nephrogonadal toxicity in rats
SY Saad et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2004)
The LKB1 tumor suppressor negatively regulates mTOR signaling
RJ Shaw et al.
CANCER CELL (2004)
Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine
NM Chandler et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2004)
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines
C Welsh et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion
X Wu et al.
BJU INTERNATIONAL (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
G Minotti et al.
PHARMACOLOGICAL REVIEWS (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy
T Sako et al.
ACTA ONCOLOGICA (2004)
Preclinical pharmacology of the taxanes: Implications of the differences
J Gligorov et al.
ONCOLOGIST (2004)
Nemo-like kinase suppresses a wide range of transcription factors, including nuclear factor-kappa B
J Yasuda et al.
CANCER SCIENCE (2004)
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
SP Thayer et al.
NATURE (2003)
Mechanisms of Taxol resistance related to microtubules
GA Orr et al.
ONCOGENE (2003)
Cisplatin: mode of cytotoxic action and molecular basis of resistance
ZH Siddik
ONCOGENE (2003)
Role of hypoxia in tumor angiogenesis - molecular and cellular angiogenic crosstalk
T Acker et al.
CELL AND TISSUE RESEARCH (2003)
Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193 - Implications for the repair of topoisomerase II-mediated DNA damage
N Adachi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Ovarian cancer: Strategies for overcoming resistance to chemotherapy
R Agarwal et al.
NATURE REVIEWS CANCER (2003)
Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells
A Mansouri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death
A Arlt et al.
ONCOGENE (2003)
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
R Bianco et al.
ONCOGENE (2003)
AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase
BA Kefas et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2003)
Biochemical modulation of cisplatin mechanisms of action:: Enhancement of antitumor activity and circumvention of drug resistance
MA Fuertes et al.
CHEMICAL REVIEWS (2003)
Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro
VP Bermudez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression
Jiyong Liang et al.
CELL CYCLE (2003)
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases
GL Johnson et al.
SCIENCE (2002)
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
S Ishida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Characterization of a novel metabolic strategy used by drug-resistant tumor cells
ME Harper et al.
FASEB JOURNAL (2002)
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
K Inoki et al.
NATURE CELL BIOLOGY (2002)
Testis-specific HMG-domain protein alters the responses of cells to cisplatin
DB Zamble et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2002)
Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells
D Meisse et al.
FEBS LETTERS (2002)
Activation of Erk1/2 and Akt in astrocytes under ischemia
ZJ Jiang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs
BAJ Jansen et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2002)
Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin
L Zou et al.
GENES & DEVELOPMENT (2002)
Hypoxia - A key regulatory factor in tumour growth
AL Harris
NATURE REVIEWS CANCER (2002)
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
NG Anderson et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Identification of genes that mediate sensitivity to cisplatin
H Niedner et al.
MOLECULAR PHARMACOLOGY (2001)
Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity
RA Kemp et al.
JOURNAL OF IMMUNOLOGY (2001)
Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase
RD DeHaan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer
XF Chen et al.
ONCOGENE (2001)
Mechanisms of resistance to cisplatin
M Kartalou et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2001)
Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein
T Imamura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Mammalian MAP kinase signalling cascades
LF Chang et al.
NATURE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Induction of apoptosis by cancer chemotherapy
SH Kaufmann et al.
EXPERIMENTAL CELL RESEARCH (2000)
Cisplatin resistance and oncogene - a review
W Dempke et al.
ANTI-CANCER DRUGS (2000)
DNA topoisomerase IIβ and neural development
X Yang et al.
SCIENCE (2000)
Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
